(+)-8-Hydroxycarvomenthon | 35866-66-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (+)-8-Hydroxycarvomenthon
• 英文别名: (1R)-8-hydroxy-trans-p-menthanone-(2)；(1R)-8-Hydroxy-trans-p-mentanon-(2)；(2R,5R)-5-(2-hydroxypropan-2-yl)-2-methylcyclohexan-1-one
• CAS: 35866-66-1
• 化学式: C₁₀H₁₈O₂
• 分子量: 170.252
• InChiKey: WZUYMVXZZRCRMY-HTQZYQBOSA-N

物化性质

• 沸点：
  263.6±13.0 °C(Predicted)
• 密度：
  1.000±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (+)-8-Hydroxycarvomenthon 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 (-)-8-Hydroxycarvomenthol
  参考文献：
  名称：

  Terpenoids. XLIX.¹ Preparation of Optically Active Polyalkylcyclohexanones from (+)-Pulegone, (-)-Menthone and (-)-Carvone²

  摘要：

  DOI：

  10.1021/ja01482a032
• 作为产物：
  描述：

  (+)-二氢香芹酮 生成 (+)-8-Hydroxycarvomenthon
  参考文献：
  名称：

  (+)-Occidentalol: Absolute Stereostructure and Total Synthesis

  摘要：

  从(+)-二氢香茅酮(3)和(+)-西洋香叶醇(2)中制备了羟基酮7，从而确定了后者的绝对立体结构。将化合物7转化为(+)-西洋香叶醇的三阶段反应构成了倍半萜的全合成。

  DOI：

  10.1139/v72-051

文献信息

• ANXIOLYTIC DEUTERATED COMPOUND AND MEDICAL USE THEREOF
  申请人：JINGLUWEIDAI INFORMATION CONSULTING SERVICE (BEIJING) CO., LTD.

  公开号：US20200095219A1

  公开（公告）日：2020-03-26

  The present invention provides compounds as represented by structural formula (I). In formula (I), R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 are separately H or deuterium (D) independently. Moreover, at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 must be D. Also provided is use of any of the compounds or its pharmaceutical composition in the preparation of a drug for treating an anxiety.

  本发明提供由结构式（I）表示的化合物。在式（I）中，R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13和R14分别独立地为氢或氘（D）。此外，R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13和R14中至少有一个必须为D。还提供使用任何一种化合物或其制药组合物制备治疗焦虑症的药物。
• Iron-catalyzed deconstructive alkylation through chlorine radical induced C–C single bond cleavage under visible light
  作者：Qiang Wu、Wei Liu、Miao Wang、Yahao Huang、Peng Hu

  DOI：10.1039/d2cc03896j

  日期：——

  Selective C–C single bond cleavage of simple compounds is a highly challenging and desired process. Herein, a chlorine radical-induced deconstructive C–C bond alkylation with alcohols and alkenes catalyzed by iron salts was reported for the first time. Readily available alcohols and various electron-deficient alkenes were tolerated. Late-stage and large-scale reactions proceed smoothly. This catalyst

  简单化合物的选择性 C-C 单键断裂是一个极具挑战性和理想的过程。在此，首次报道了氯自由基诱导的由铁盐催化的醇和烯烃的解构C-C键烷基化反应。容易获得的醇和各种缺电子烯烃是可以耐受的。后期和大规模反应顺利进行。该催化剂体系显示出对简单 C-C 键进行多样化解构功能化的潜力。
• ANTIANXIETY DEUTERATED COMPOUNDS AND MEDICAL USE THEREOF
  申请人：Jingluweidai Information Consulting Service (Beijing) Co Ltd

  公开号：EP3611170A1

  公开（公告）日：2020-02-19

  The present invention provides compounds as represented by structural formula (I). In formula (I), R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 are separately H or deuterium (D) independently. Moreover, at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 must be D. Also provided is use of any of the compounds or its pharmaceutical composition in the preparation of a drug for treating an anxiety.

  本发明提供了结构式（I）所代表的化合物。在式 (I) 中，R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13 和 R14 分别独立地为 H 或氘 (D)。此外，R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13 和 R14 中至少有一个必须是 D。还提供了任一化合物或其药物组合物在制备治疗焦虑症的药物中的用途。
• Anxiolytic deuterated compound and medical use thereof
  申请人：BEIJING JUNKE HUAYUAN MED TECH CO., LTD.

  公开号：US11358944B2

  公开（公告）日：2022-06-14

  The present invention provides compounds as represented by structural formula (I). In formula (I), R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 are separately H or deuterium (D) independently. Moreover, at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 must be D. Also provided is use of any of the compounds or its pharmaceutical composition in the preparation of a drug for treating an anxiety.

  本发明提供了结构式（I）所代表的化合物。在式 (I) 中，R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13 和 R14 分别独立地为 H 或氘 (D)。此外，R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13 和 R14 中至少有一个必须是 D。还提供了任一化合物或其药物组合物在制备治疗焦虑症的药物中的用途。
• DEUTERATED COMPOUNDS AND MEDICAL USE THEREOF AS ANTIANXIETY AGENTS
  申请人：BEIJING JUNKE HUAYUAN MED TECH CO., LTD.

  公开号：EP3611170B1

  公开（公告）日：2022-01-26